Listen

Description

In this final episode of the Progesterone Promise series, Dr. Brendan McCarthy, Chief Medical Officer of Protea Medical Center, breaks down one of the most misunderstood hormones in women’s health: progesterone.

Progesterone is not “good” or “bad.” It’s contextual.

In today’s world of quick sound bites and social media medicine, hormones are often reduced to oversimplified claims like “progesterone fixes anxiety” or “progesterone causes breast cancer.” The truth? It depends on your body, your stress levels, your liver health, your inflammation, your delivery method, and whether you're using bioidentical progesterone or synthetic progestins.

 

Citations:


1. Oral Progesterone → First-Pass Metabolism & Allopregnanolone

Claim:
Oral micronized progesterone undergoes significant hepatic first-pass metabolism, increasing neuroactive metabolites (especially allopregnanolone), which positively modulate GABA-A receptors and produce sedative/anxiolytic effects.

Core Evidence:

Supports:
Sedation variability by route • Neurosteroid generation • GABA-A modulation

2. Sulfation vs 5α-Reduction → Opposing Neurologic Effects

Claim:
Progesterone metabolites can produce calming (5α-reduced) or excitatory (sulfated) neurologic effects depending on enzyme routing.

Core Evidence:

Supports:
Reverse responding hypothesis • Divergent neurologic experiences • Enzyme-dependent effects

3. Stress & Enzyme Modulation

Claim:
Chronic stress alters HPA axis tone and hepatic enzyme expression, influencing steroid metabolism balance.

Core Evidence:

Supports:
Stress-biased metabolism • Context-dependent hormone response

4. Breast Tissue Signaling & Context

Claim:
Progesterone influences mammary differentiation and interacts with estrogen signaling in context-dependent ways.

Core Evidence:

Supports:
Lobuloalveolar differentiation • RANKL pathway • Context-dependent proliferation

5. Synthetic Progestins vs Bioidentical Progesterone

Claim:
Synthetic progestins differ structurally and bind off-target receptors, producing distinct tissue effects.

Core Evidence:

Supports:
Structural divergence • Receptor-level differences • WHI clarification

6. Route of Delivery Differences

Claim:
Oral, vaginal, transdermal, and sublingual progesterone produce distinct pharmacokinetic profiles and tissue targeting.

Core Evidence:

Supports:
Uterine targeting • Neurosteroid variability • Sedation differences

7. Progesterone, PMS & Migraine

Claim:
Neurosteroid fluctuations influence GABAergic tone and may contribute to PMS and migraine susceptibility.

Core Evidence:

Supports:
Luteal neurosteroid shifts • GABA instability • Migraine association

 

Dr. Brendan McCarthy is the founder and Chief Medical Officer of Protea Medical Center in Arizona. With over two decades of experience, he’s helped thousands of patients navigate hormonal imbalances using bioidentical HRT, nutrition, and root-cause medicine. He’s also taught and mentored other physicians on integrative approaches to hormone therapy, weight loss, fertility, and more. If you’re ready to take your health seriously, this podcast is a great place to start.

 

👇 Tap Subscribe to learn more about what’s actually happening in your body, and what to do about it.

 

📘 Read Dr. McCarthy’s Book: Jump Off the Mood Swing – A Sane Woman’s Guide to Her Crazy Hormones https://www.amazon.com/Jump-Off-Mood-Swing-Hormones/dp/0999649604

 

📲 Follow Dr. McCarthy:

Instagram: @drbrendanmccarthy

TikTok: @drbrendanmccarthy

Website: www.protealife.com

 

💬 Got a question or topic for a future episode? Let us know in the comments!